4,032 results match your criteria Budd-Chiari Syndrome


Long-term outcomes of interventional treatment for Budd-Chiari syndrome with chronic accessory hepatic vein obstruction.

Eur J Gastroenterol Hepatol 2020 May 29. Epub 2020 May 29.

Department of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University.

Objective: Interventional treatment is the main therapy for Budd-Chiari syndrome (BCS) with hepatic vein obstruction. The aim of this study was to investigate the long-term outcomes of endovascular management for BCS with chronic accessory hepatic vein (AHV) obstruction.

Methods: In total, 68 patients with primary BCS who underwent AHV dilation with or without stenting from January 2008 to December 2018 were included in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001784DOI Listing

Right atrial mass in a patient with hepatocellular carcinoma and Budd-Chiari syndrome.

North Clin Istanb 2020 9;7(3):292-293. Epub 2020 Apr 9.

Department of Cardiology, University of Health Sciences, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14744/nci.2019.35002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251274PMC

Therapeutic coil embolization of dominant shunt in hepatopulmonary syndrome enhances post-liver transplant respiratory recovery.

Pediatr Transplant 2020 May 21:e13729. Epub 2020 May 21.

Department of Liver Transplantation and HPB Surgery, Apollo Hospitals, Navi Mumbai, India.

Coil embolization of the atypical enlarged pulmonary artery/arteriole with visible shunting may improve hypoxemia in patients with hepatopulmonary syndrome (HPS). When used selectively in cases with large shunts, either pre- or post-liver transplantation (LT), it can aid an early recovery and reduce morbidity. We present a case where a large intrapulmonary shunt was embolized preoperatively to improve hypoxemia associated with HPS and enhance post-operative recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13729DOI Listing
May 2020
1.630 Impact Factor

Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome.

JHEP Rep 2020 Jun 9;2(3):100097. Epub 2020 Mar 9.

Department of Radiology, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, Clichy, France.

Background & Aims: Hepatobiliary phase (HBP) images can discriminate between benign and malignant liver lesions, but it is unclear if this approach can be used in patients with Budd-Chiari syndrome (BCS). Thus, we aimed to assess the diagnostic utility of HBP images in patients with BCS.

Methods: This retrospective study included all patients admitted to our institution with a diagnosis of BCS and focal liver lesions on hepatobiliary contrast agent-enhanced MR imaging (HBCA-MRI) from 2000 to 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhepr.2020.100097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232085PMC

Sequential interventional therapy for Budd-Chiari syndrome associated with fresh inferior vena cava thrombosis.

J Vasc Surg Venous Lymphat Disord 2020 May 14. Epub 2020 May 14.

Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address:

Objective: Our study aimed to evaluate the safety and efficacy of sequential interventional therapy for Budd-Chiari syndrome (BCS) caused by obstruction of the inferior vena cava (IVC) with fresh thrombus in the IVC.

Methods: Full medical records were obtained for 20 patients with BCS associated with fresh IVC thrombus who received sequential interventional therapy from 2014 to 2019 at our hospital. All patients underwent small-diameter percutaneous transluminal angioplasty (PTA) balloon catheter predilation combined with sequential catheter-directed thrombolysis and large-diameter PTA balloon dilation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvsv.2020.03.005DOI Listing

Venous thrombosis of the liver: current and emerging concepts in management.

Authors:
Leonard Naymagon

Transl Res 2020 May 11. Epub 2020 May 11.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. Electronic address:

Venous thrombosis within the hepatic vasculature is associated with a distinct array of risk factors, characteristics, and potential complication. As such, it entails unique management considerations and strategies relative to the more common categories of venous thromboembolic disease. Although broadly divided into thrombosis of the afferent vasculature (the portal venous system) and efferent vasculature (the hepatic venous system), presentations and management strategies within these groupings are heterogeneous. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trsl.2020.04.012DOI Listing

Epstein-Barr Virus and Cytomegalovirus Infections of the Liver.

Gastroenterol Clin North Am 2020 Jun;49(2):331-346

Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address:

Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections are common and are associated with a variety of liver manifestations. EBV and CMV infections, in immunocompetent hosts, commonly manifest as acute hepatitis, with severity varying from asymptomatic, self-limited icteric hepatitis to acute liver failure. Atypical manifestations, such as cholestasis, chronic hepatitis, precipitation of acute-on-chronic liver failure, and autoimmune hepatitis, are reported with EBV infection, whereas cholestasis, portal vein thrombosis, and Budd-Chiari syndrome are reported with CMV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gtc.2020.01.008DOI Listing

[Etiological diagnosis and clinical evaluation of isolated fetal ascites].

Zhonghua Fu Chan Ke Za Zhi 2020 Apr;55(4):246-252

Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.

To explore the correlation between prenatal clinical data with etiological diagnosis and neonatal outcome in isolated fetal ascites. Totally, 36 pregnancy cases diagnosed as isolated fetal ascites by ultrasound in Provincial Hospital Affiliated to Shandong University from June 22nd, 2016 to September 28th, 2018 were collected. Invasive prenatal diagnosis was performed by taking fetal cord blood, amniotic fluid, and fetal ascites respectively for cytogenetics, molecular genetics and biochemical examination and the impact of intrauterine therapeutic procedures on neonatal outcomes was evaluated as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112141-20190605-00312DOI Listing

Behcet's Disease With Budd-Chiari Syndrome and Challenges in Its Management.

ACG Case Rep J 2020 Mar 19;7(3):e00352. Epub 2020 Mar 19.

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.

Budd-Chiari syndrome may rarely occur as a complication of Behcet's disease, and presentation with thrombosis of both inferior vena cava (IVC) and hepatic veins is rarer still. We present a young woman with Behcet's disease who presented with acute Budd-Chiari syndrome, with thrombosis of IVC and all 3 hepatic veins. An IVC stent was placed, followed by a transjugular intrahepatic portosystemic shunt through the IVC stent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.0000000000000352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162122PMC

Agreed diagnostic criteria needed for Budd-Chiari syndrome.

Authors:
Andrea Mancuso

Br J Radiol 2020 Jun 20;93(1110):20200259. Epub 2020 Apr 20.

Medicina Interna 1, ARNAS Civico - Di Cristina - Benfratelli, Piazzale Leotta 4, Palermo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20200259DOI Listing

Controversies in Budd-Chiari Syndrome Management: Potential Role of Liver Stiffness.

Am J Gastroenterol 2020 Jun;115(6):952-953

Medicina Interna 1, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000586DOI Listing

Budd-Chiari syndrome.

Clin Res Hepatol Gastroenterol 2020 Apr 2. Epub 2020 Apr 2.

French Network for Rare Liver Diseases FILFOIE, Saint-Antoine Hospital, APHP, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France; Department of Gastroenterology and Hepatology, Rangueil Hospital, University Hospital of Toulouse, 1, avenue du Professeur Jean-Poulhès, 31400 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2020.03.015DOI Listing

Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats.

World J Gastrointest Pathophysiol 2020 Mar;11(1):1-19

Departments of Pharmacology and Pathology, Medical Faculty University of Zagreb, Zagreb 10000, Croatia.

Background: Recently, as a possible therapy resolving solution, pentadecapeptide BPC 157 therapy, has been used in alleviating various vascular occlusion disturbances. BPC 157 was previously reviewed as novel mediator of Robert cytoprotection and endothelium protection in the stomach, and gut-brain axis, beneficial therapy in gastrointestinal tract, with particular reference to vascular recruitment, ulcerative colitis and tumor cachexia, and other tissues healing. Here we raised new hypothesis about BPC 157 therapy in the Budd-Chiari syndrome in rats, rapid bypassing of the suprahepatic inferior caval vein occlusion, and rats recovery with the active and effective pharmacotherapy treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4291/wjgp.v11.i1.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093306PMC

Inferior Vena Cava Rupture Caused by Perforation Route through a Collateral Vein during Endovascular Treatment of Budd-Chiari Syndrome: Case Report.

Ann Vasc Surg 2020 Mar 20. Epub 2020 Mar 20.

Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Budd-Chiari syndrome (BCS) is an uncommon disorder defined as an obstruction of the hepatic venous outflow. Percutaneous transluminal balloon angioplasty is a less invasive treatment option for BCS patients. However, there are no reports regarding inferior vena cava (IVC) rupture caused by perforation route through a collateral vein during treatment of BCS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.avsg.2020.02.030DOI Listing
March 2020
1.029 Impact Factor

Percutaneous stenting of left hepatic vein followed by Ex vivo Liver Resection and Autotransplantation in a patient with hepatic alveolar echinococcosis with Budd-Chiari syndrome.

Int J Surg Case Rep 2020 9;68:251-256. Epub 2020 Mar 9.

Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong Special Administrative Region. Electronic address:

Background And Aims: Infiltration of hepatic venous outflow in hepatic alveolar echinococcosis can lead to development of Budd-Chiari syndrome. Medical treatment of this condition is generally unsatisfactory. Radical hepatic resection is impossible for extensive parasitic involvement of liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2020.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082604PMC

Non-amyloid liver involvement in familial Mediterranean fever: A systematic literature review.

Liver Int 2020 Jun 15;40(6):1269-1277. Epub 2020 Apr 15.

Service de médecine interne, Hôpital Tenon, APHP, Université Sorbonne, Paris, France.

Introduction: Familial Mediterranean fever (FMF), the most frequent autoinflammatory disease, is caused by mutations in the MEFV gene. It is characterized by recurrent febrile attacks of polyserositis. Liver abnormalities may develop during its course, but they remain poorly defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14445DOI Listing

Diagnostic accuracy of Doppler ultrasound, CT and MRI in Budd Chiari syndrome: systematic review and meta-analysis.

Br J Radiol 2020 May 18;93(1109):20190847. Epub 2020 Mar 18.

Gastroenterology, PGIMER, Chandigarh, India.

Objective: To evaluate the sensitivity, specificity, and diagnostic odds ratio (DOR) of Doppler ultrasound, CT, and MRI in the diagnosis of Budd Chiari syndrome (BCS).

Methods: We performed a literature search in PubMed, Embase, and Scopus to identify articles reporting the diagnostic accuracy of Doppler ultrasound, CT, and MRI (either alone or in combination) for BCS using catheter venography or surgery as the reference standard. The quality of the included articles was assessed by using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20190847DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217562PMC

Budd-Chiari Syndrome: An Unusual Complication of AL Amyloidosis

Turk J Haematol 2020 05 4;37(2):130-131. Epub 2020 Mar 4.

İstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4274/tjh.galenos.2020.2019.0186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236407PMC

[Treatment strategies of Budd-Chiari syndrome during the epidemic period of 2019 coronavirus disease].

Zhonghua Wai Ke Za Zhi 2020 Feb 28;58(0):E007. Epub 2020 Feb 28.

Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Zhengzhou University, Budd-Chiari Syndrome Diagnosis and Treatment Center of Henan Province, Zhengzhou 450052, China.

Prevention and control about the situation of 2019 coronavirus disease (COVID-19) are grim at present. In addition to supporting the frontline actively, medical workers in general surgery spare no efforts in making good diagnosis and treatment of specialized diseases by optimizing treatment process, providing medical advice online, mastering indications of delayed operation and emergency operation reasonably, etc. Budd-Chiari syndrome is a complex disorder, and severity of the disease varies, serious cases can be life threatening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112139-20200221-00109DOI Listing
February 2020

A Comparison of Splenic Pathologic Change and Immune Function in HBV-Related Portal Hypertension and Chinese Budd-Chiari Syndrome Patients with Hypersplenism.

Viral Immunol 2020 Mar 26;33(2):112-121. Epub 2020 Feb 26.

National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

The difference of splenic pathologic alterations and immune function changes in portal hypertension (PHT) with different etiology is unclear. We aimed to investigate the differences between the hypersplenic patients with hepatitis B virus (HBV)-related PHT and Budd-Chiari syndrome (B-CS). A total of 93 patients with hypersplenism due to Chinese primary B-CS (B-CS group), 105 patients with hypersplenism due to HBV-related cirrhosis (HBV/PHT group), and 31 healthy people (control group) were included in this study retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/vim.2019.0146DOI Listing
March 2020
1.636 Impact Factor

Chronic Budd-Chiari syndrome in Behçet's disease successfully managed with transjugular intrahepatic portosystemic shunt: a case report and literature review.

Clin J Gastroenterol 2020 Feb 17. Epub 2020 Feb 17.

Venous Thromboembolism Unit, Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, C/. Doctor Esquerdo, 46, 28007, Madrid, Spain.

Budd-Chiari syndrome (BCS) is characterized by an obstruction of hepatic venous outflow from small hepatic veins to inferior vena cava, caused by acute thrombosis or its fibrous sequellae. An underlying myeloproliferative neoplasm is present in 50% of cases. Clinical manifestations are widely variable, from asymptomatic to fulminant episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-020-01106-7DOI Listing
February 2020

Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients.

Dig Dis Sci 2020 Feb 15. Epub 2020 Feb 15.

Division of Gastroenterology and Hepatology, Newark University Hospital/Rutgers - New Jersey Medical School, Newark, NJ, USA.

Background: It has been reported that transjugular intrahepatic portosystemic shunting (TIPS) might be utilized as a salvage option for hepatorenal syndrome (HRS), while randomized controlled trials are pending and real-world contemporary data on inpatient mortality is lacking.

Methods: We conducted an observational retrospective cohort study from the National Inpatient Sample from 2005 to 2014. We included all adult patients admitted with HRS and cirrhosis, using ICD 9-CM codes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-020-06136-2DOI Listing
February 2020

Inferior vena cava obstruction in Budd-Chiari syndrome: a comparative study of rapid quantitative phase-contrast MRI and MRV.

Abdom Radiol (NY) 2020 04;45(4):1069-1074

Department of Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.

Purpose: The purpose of this study was to analyze inferior vena cava (IVC) obstruction in Budd-Chiari syndrome (BCS) using rapid quantitative phase-contrast (PC) magnetic resonance (MR) imaging and compare the diagnostic efficacy of PC and MR venography (MRV) to explore the clinical prospects of applying PC quantitative diagnosis in IVC obstruction in BCS.

Materials And Methods: PC quantitative data and MRV qualitative data obtained in 35 DSA-recognized inferior vena cava obstruction in BCS patients and 35 patients with liver focal lesions found in physical examination were analyzed and compared.

Results: The areas under the ROC curve for diagnostic parameters related to PC quantitative parameters, including stroke volume, forward flow volume, absolute stroke volume, mean flux, stroke distance, mean velocity (MV), and peak velocity, were 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-02394-5DOI Listing

Explant liver evaluation decodes the mystery of cryptogenic cirrhosis!

JGH Open 2020 Feb 30;4(1):39-43. Epub 2019 May 30.

Institute of GI Sciences and Liver Transplantation Gleneagles Global Health City Chennai India.

Background And Aim: To determine the concordance of liver explants with the pretransplant diagnosis.

Methods: This was a retrospective analysis of 251 liver explants. Patient information included demography, comorbidity, and etiological diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgh3.12200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008160PMC
February 2020

How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.

Hamostaseologie 2020 Feb 12;40(1):47-53. Epub 2020 Feb 12.

Department of Medicine (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), Faculty of Medicine, RWTH Aachen University, Aachen, Germany.

Patients with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are at increased risk for arterial and venous thrombosis/thromboembolism. In particular, the risk of splanchnic venous thrombosis, such as portal vein thrombosis or Budd-Chiari syndrome, is significantly higher in patients with MPN than in the normal population. At the same time, MPN patients are at increased risk for severe bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0040-1701474DOI Listing
February 2020

Successful pregnancy in a liver transplant patient of Budd-Chiari syndrome.

BMJ Case Rep 2020 Feb 9;13(2). Epub 2020 Feb 9.

Obstetrics & Gynaecology, Services Hospital, Lahore, Punjab, Pakistan.

In recent years, the number of patients undergoing liver transplant has increased. Successful transplant has resulted in better quality of life and improved fertility in younger women. This is a case study a 31-year-old woman, who had history of Budd-Chiari syndrome and underwent liver transplantation in 2014 with uneventful postoperative course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-229315DOI Listing
February 2020

Accessory hepatic vein recanalization for hepatic vein-type Budd-Chiari syndrome.

Minim Invasive Ther Allied Technol 2020 Feb 5:1-6. Epub 2020 Feb 5.

Department of Radiology, Xuzhou Central Hospital, Xuzhou, China.

To explore the clinical efficacy and long-term outcomes of accessory hepatic vein (AHV) recanalization as a means of treating hepatic vein (HV)-type Budd-Chiari syndrome (BCS). Between January 2011 and December 2018, a total of 46 symptomatic HV-type BCS patients were treated by AHV recanalization in our hospital. The technical and clinical success of this treatment, as well as associated long-term patient prognosis was assessed herein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13645706.2020.1723110DOI Listing
February 2020

Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.

BMC Gastroenterol 2020 Feb 4;20(1):30. Epub 2020 Feb 4.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Background: One major etiology of hepatic sinusoidal obstruction syndrome (HSOS) in China is the intake of pyrrolizidine alkaloids (PAs). Since PAs-induced HSOS is a rare disease that has not been clearly characterized until now, the aim of this study was to investigate clinical characteristics, CT features, and pathological findings of PA-induced HSOS.

Methods: This retrospective cohort study included 116 patients with PAs-induced HSOS and 68 patients with Budd-Chiari syndrome from Jan 2006 to Sep 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-020-1180-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001201PMC
February 2020
2.365 Impact Factor

Is There Still a Role for Surgical Shunts in the Treatment of Budd-Chiari Syndrome? A 25-Year Experience.

J Gastrointest Surg 2020 Feb 3. Epub 2020 Feb 3.

HPB Surgery Unit, Department of General Surgery,Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Purpose: To investigate the long-term results of shunt surgery in the treatment of Budd-Chiari Syndrome.

Methods: Medical records of patients treated with Budd-Chiari Syndrome between 1993 and 2006 were reviewed.

Results: Thirty-seven patients (26 female, 11 male) were identified, with a median age of 30 years (range 14-51). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-020-04524-7DOI Listing
February 2020

Why and when to diagnose Behcet's disease in patients with Budd Chiari Syndrome?

Clin Res Hepatol Gastroenterol 2020 Jan 6. Epub 2020 Jan 6.

Department of Hepatology, DHU Unity, Beaujon Hospital, AP-HP, 100, boulevard du Général Leclerc 92118 Clichy, France; University of Paris, center for research in inflammation, Inserm, 75018 Paris, France; Reference center of vascular liver diseases, French Network for Rare Liver Diseases (FILFOIE), Paris, France; European Reference Network (ERN) Rare-Liver, ERN rare liver Hamburg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2019.12.003DOI Listing
January 2020

Anticoagulating Budd-Chiari syndrome patients presenting with variceal bleed: A retrospective study.

J Gastroenterol Hepatol 2020 Jan 3. Epub 2020 Jan 3.

Department of Hepatology, Christian Medical College, Vellore, India.

Background And Aim: This aims to study incidence of re-bleeding on anticoagulation and survival of Budd-Chiari syndrome (BCS) patients presenting with variceal bleeding.

Methods: Budd-Chiari syndrome patients presenting with variceal bleed between 01/01/2007 and 01/05/2019 were retrospectively studied. Patients underwent endoscopic treatment ± endovascular therapy, followed by anticoagulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.14971DOI Listing
January 2020
3.504 Impact Factor

Double-hit monomorphic B-cell lymphoma after liver transplantation.

BMJ Case Rep 2020 Jan 2;13(1). Epub 2020 Jan 2.

Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

We report the first case of double-hit (MYC and BCL-6) monomorphic post-transplant lymphoproliferative disorder in a patient status post liver transplantation. Our patient is a 71-year-old man with a past medical history of Budd-Chiari syndrome complicated by cirrhosis and hepatocellular carcinoma. He underwent a deceased donor liver transplantation 2 years prior to presentation and was maintained on tacrolimus and mycophenolate mofetil for immunosuppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-231831DOI Listing
January 2020

Acute-on-Chronic Liver Failure in Budd-Chiari Syndrome: Profile and Predictors of Outcome.

Dig Dis Sci 2020 Jan 2. Epub 2020 Jan 2.

Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.

Background And Aim: There is a paucity of data on the clinical presentations and outcome of Budd-Chiari syndrome (BCS) patients presenting as acute-on-chronic liver failure (BCS-ACLF). We aimed to describe the profile and outcomes of endovascular interventions in patients with BCS-ACLF.

Methods: All BCS-ACLF patients presenting between October 2007 and April 2019 satisfying the Asian Pacific Association for the Study of the Liver (APASL) definition were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-019-06005-7DOI Listing
January 2020
2.550 Impact Factor

Budd-Chiari Syndrome after Bilateral Nephrectomy for Polycystic Kidney Disease in a Kidney Transplant Recipient.

Urol Int 2020 2;104(3-4):330-332. Epub 2020 Jan 2.

Division of Nephrology, Hospital do Rim, Federal University of São Paulo, São Paulo, Brazil.

We report a rare case of Budd-Chiari syndrome (BCS) as a postoperative complication after bilateral nephrectomy in a kidney transplant recipient with polycystic liver and kidneys. Contrast-enhanced computed tomography of the abdomen showed a narrowed inferior vena cava, compressed by the polycystic liver that moved downwards after nephrectomy. A stenting angioplasty was performed, resulting in remarkable clinical improvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504514DOI Listing
January 2020

Budd-Chiari syndrome presenting with abdominal wall varices.

Korean J Intern Med 2019 Dec 30. Epub 2019 Dec 30.

Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2019.384DOI Listing
December 2019

Deceased donor liver transplantation for Budd-Chiari syndrome: Long-segmental thrombosis of the inferior vena cava with extensive collateral circulation.

Hepatobiliary Pancreat Dis Int 2019 Dec 4. Epub 2019 Dec 4.

Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing 100020, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hbpd.2019.11.008DOI Listing
December 2019

Left trisectionectomy and supra-hepatic caval reconstruction with vascular prosthesis for chronic Budd-Chiari syndrome caused by hepatic alveolar echinococcosis.

Chin Med J (Engl) 2019 Dec;132(23):2886-2888

Department of Hepatobiliary & Hydatid Disease, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000521DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940081PMC
December 2019

Thrombotic Storm With Budd-Chiari Syndrome in a Pediatric Patient With Ulcerative Colitis.

ACG Case Rep J 2019 Oct 25;6(10):e00159. Epub 2019 Oct 25.

Division of Pediatric Gastroenterology, Hackensack University Medical Center, Hackensack, NJ.

Ulcerative colitis is associated with an increased risk of thromboembolic phenomena. Thrombotic storm defined by the development of multiple thrombi in multiple locations within a short period of time is a rare condition that is potentially life threatening. We present a 14-year-old adolescent boy with an ulcerative colitis flare complicated by Budd-Chiari syndrome and thrombotic storm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.0000000000000159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855525PMC
October 2019

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Hematology Am Soc Hematol Educ Program 2019 12;2019(1):397-406

Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

Thrombotic and hemorrhagic complications are prevalent in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is a major therapeutic goal. Historically, patients have been risk stratified on the basis of traditional factors, such as advanced age and thrombosis history. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/hematology.2019001318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913438PMC
December 2019

Progressive dyspnea and a right atrial mass in an 80-year-old man.

Autops Case Rep 2019 Oct-Dec;9(4):e2019135. Epub 2019 Nov 27.

Universidade de São Paulo (USP), Medical School, Heart Institute, General Outpatient Clinics, Division of Clinical Cardiology. São Paulo, SP, Brazil.

Hepatocellular carcinoma (HCC) is among the five most frequent causes of cancer death worldwide, according to the WHO. The disease is related to alcohol abuse, viral infections, and other causes of cirrhosis, and unfortunately, in some developed countries, the incidence shows an increasing trend. Although the diagnosis of the HCC often relies upon the context of a chronic hepatopathy, some cases may present a silent course, and the initial symptoms ensue when the disease is in an advanced stage with no chance for any therapeutic attempt. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4322/acr.2019.135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880769PMC
November 2019

Obstructed membranous transformation of the inferior vena cava in patients with hepatic vein-type Budd-Chiari syndrome: A case series.

Clin Res Hepatol Gastroenterol 2020 Apr 27;44(2):e17-e24. Epub 2019 Nov 27.

Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:

Budd-Chiari syndrome (BCS) is a rare disease characterized by the obstruction of hepatic venous outflow due to occlusion of the hepatic vein (HV) or the inferior vena cava (IVC). The pathophysiology of IVC and HV membranous transformation, which can form in isolation or simultaneously, remains unclear in patients with combined-type BCS. Here we report three cases of patients with BCS demonstrating conversion from HV-type to combined-type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2019.10.008DOI Listing
April 2020
1.983 Impact Factor

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Blood 2019 11;134(22):1902-1911

Thrombotic and hemorrhagic complications are prevalent in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is a major therapeutic goal. Historically, patients have been risk stratified on the basis of traditional factors, such as advanced age and thrombosis history. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019001318DOI Listing
November 2019

Budd-Chiari Syndrome in a Patient With Simultaneous Diagnosis of Hepatic Sarcoidosis and Nodular Regenerative Hyperplasia.

ACG Case Rep J 2019 Sep 12;6(9):e00200. Epub 2019 Sep 12.

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA.

Budd-Chiari syndrome (BCS) is a rare vascular disorder characterized by an obstruction of the hepatic venous outflow. Nodular regenerative hyperplasia (NRH) may develop as a result of an underlying autoimmune disease such as hepatic sarcoidosis. Only a few case reports have described cases with either NRH or hepatic sarcoidosis associated with BCS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.0000000000000200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831147PMC
September 2019

Noninvasive imaging diagnosis of sinusoidal obstruction syndrome: a pictorial review.

Insights Imaging 2019 Nov 20;10(1):110. Epub 2019 Nov 20.

Department of Radiology, Sichuan University West China Hospital, No.37, Guoxue Alley, Chengdu, 610041, Sichuan Province, China.

Sinusoidal obstruction syndrome (SOS) is a rare liver disorder due to hepatic vascular injury. Its rapid and accurate diagnosis is crucial for patient survival. SOS is often established clinically, based on Baltimore, modified Seattle, or European Society for Blood and Marrow Transplantation (EBMT) criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13244-019-0791-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868080PMC
November 2019
4 Reads

Characteristics and outcome of primary Budd-Chiari syndrome due to Behçet's syndrome.

Clin Res Hepatol Gastroenterol 2019 Nov 14. Epub 2019 Nov 14.

Department of Radiodiagnosis & Interventional Radiology, Ain Shams University, Cairo, 11341 Abbasia, Egypt.

Background And Aim: Behçet's syndrome (BS) is a known cause of Budd-Chiari syndrome (BCS). We aimed at identifying the prevalence of BS in patients with BCS, analyzing different clinical presentations, treatment modalities and outcome of these patients.

Methods: We conducted a retrospective cohort study, in which all medical records of patients who were presented to Tropical Medicine Department, Ain Shams University with a confirmed diagnosis of primary BCS from May 2005 to December 2016 were collected and analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2019.10.006DOI Listing
November 2019
42 Reads

Pediatric Hepatic Venous Outflow Tract Obstruction: Experience from a Transplant Center.

Indian Pediatr 2019 11;56(11):965-967

Department of Liver Transplantation and Hepatobiliary Surgery, Indraprastha Apollo Hospitals, New Delhi, India.

We performed a review of case records of children diagnosed with hepatic venous outflow tract obstruction at our center in last 10 years. Out of 11 cases identified, 6 had variable blocks in the hepatic venous system and 4 had combined hepatic venous and inferior vena cava (IVC) block. One child with paroxysmal nocturnal hemoglobinuria (PNH) had isolated IVC involvement. Read More

View Article

Download full-text PDF

Source
November 2019

Left trisectionectomy and supra-hepatic caval reconstruction with vascular prosthesis for chronic Budd-Chiari syndrome caused by hepatic alveolar echinococcosis.

Chin Med J (Engl) 2019 Nov 12. Epub 2019 Nov 12.

Department of Hepatobiliary & Hydatid Disease, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000521DOI Listing
November 2019

A rare case of association between Budd-Chiari syndrome and sea-blue histiocytosis.

Authors:
F Hu Y Zhang Z Yi

Niger J Clin Pract 2019 Nov;22(11):1617-1620

Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, China.

Budd-Chiari syndrome (BCS) is a rare disease characterized by obstruction of hepatic venous outflow tract with diversified etiologies. Sea-blue histiocytosis (SBH) is a kind of storage diseases defined by the deposition of abundant sea-blue histiocytes in various organs and can lead to hepatosplenomegaly, cirrhosis, or even liver failure. The association between BCS and SBH has never been reported before. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/njcp.njcp_43_19DOI Listing
November 2019
5 Reads